Carcinoma, Renal Cell: Clinical Trials

1,968 trials for Carcinoma, Renal Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

917 completed, 282 terminated, 266 recruiting, 189 unknown. 820 Phase 2, 610 Phase 1, 229 Not applicable, 122 Phase 3, 32 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2820Completed 363, Terminated 146, Recruiting 101, Unknown 84, Active not recruiting 62, Withdrawn 33, Not yet recruiting 25, Suspended 4, Enrolling by invitation 2
Phase 1610Completed 283, Terminated 113, Recruiting 81, Active not recruiting 61, Unknown 40, Withdrawn 15, Not yet recruiting 10, Suspended 7
Not applicable229Completed 78, Recruiting 46, Unknown 37, Terminated 24, Withdrawn 17, Not yet recruiting 14, Active not recruiting 9, Enrolling by invitation 2, Suspended 2
Phase 3122Completed 61, Active not recruiting 20, Recruiting 15, Terminated 12, Unknown 5, Not yet recruiting 4, Withdrawn 4, Enrolling by invitation 1
Early Phase 132Completed 18, Recruiting 4, Active not recruiting 3, Terminated 2, Withdrawn 2, Not yet recruiting 1, Suspended 1, Unknown 1
Phase 426Completed 15, Recruiting 5, Terminated 4, Unknown 2

Follow Carcinoma, Renal Cell: new trials by email Literature Review of Carcinoma, Renal Cell trials Research Report on Carcinoma, Renal Cell

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)162027-05-172026-11-20
Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer
Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer)
Phase 2Not yet recruitingBeth Israel Deaconess Medical Center102027-04-262026-11-09
Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma
Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 3Not yet recruitingNational Cancer Institute (NCI)4002027-02-102026-07-08
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma
Phase 2Not yet recruitingFujian Cancer Hospital272027-02-012026-10-01
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
Not applicableNot yet recruitingNatera, Inc.9202027-01-012026-10-27
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma
Phase 1Not yet recruitingAccSalus Biosciences, Inc.402027-01-012026-10-28
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
Neoadjuvant Pembrolizumab, Belzutifan, Lenvatinb - Renal Cell Carcinoma
Phase 2Not yet recruitingVall d'Hebron Institute of Oncology1502027-01-012026-11-12
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1Not yet recruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company1122026-12-312026-09-30
Metabolism And Diet for Improving Kidney Cancer Health (MACH3)
Health Coaching, Time-Restricted Eating, Mediterranean Diet - Renal Cell Carcinoma
Not applicableNot yet recruitingUniversity of Miami302026-12-212026-11-18
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma
Phase 2Not yet recruitingPeter MacCallum Cancer Centre, Australia302026-12-012026-10-26
Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma
Phase 1Not yet recruitingJonsson Comprehensive Cancer Center182026-12-012026-08-06
A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
Envafolimab+Lenvatinib - Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis
Phase 2Not yet recruitingFudan University302026-12-012026-09-09
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Phase 2Not yet recruitingFred Hutchinson Cancer Center502026-12-012026-09-17
Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma
Carcinoma, Renal Cell, Inferior Vena Cava Tumor Thrombus
Not yet recruitingLiu Zhuo2732026-11-302026-10-28
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Phase 2Not yet recruitingCity of Hope Medical Center342026-11-282026-05-11
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer
Phase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.5582026-11-152026-11-12
AI-Based Anatomy Recognition in Minimally Invasive Kidney Surgery
AI-based intra-operative anatomical perception system - Kidney (Renal Cell) Cancer, Ureteropelvic Junction Obstruction
Not yet recruitingChinese PLA General Hospital17002026-11-152026-11-17
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Pucotenlimab, Lenvatinib, Stereotactic Body Radiotherapy - Localized Clear Cell Renal Cell Carcinoma
Phase 2Not yet recruitingSun Yat-sen University242026-11-102026-11-06
Evaluation of Safety, Pharmacokinetics, Distribution,Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
68Ga-NYM096 injection - Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1RecruitingNorroy Bioscience Co., LTD202026-11-082026-11-19
Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)
Bio-specimen Collection, Blood Draw - Prostate Cancer, Renal Cell Carcinoma (RCC)
RecruitingUniversity of Oklahoma3002026-11-022026-10-13

Showing 20 of 1968. Sign in to see all of them.

Narrower conditions

Kidney Neoplasms (480)  ·  Melanoma (290)  ·  Carcinoma, Non-Small-Cell Lung (285)  ·  Neoplasm Metastasis (170)  ·  Neoplasms (158)  ·  Colorectal Neoplasms (147)  ·  Breast Neoplasms (142)  ·  Carcinoma, Hepatocellular (135)  ·  Ovarian Neoplasms (120)  ·  Squamous Cell Carcinoma of Head and Neck (116)  ·  Stomach Neoplasms (115)  ·  Urinary Bladder Neoplasms (115)  ·  Pancreatic Neoplasms (109)  ·  Prostatic Neoplasms (101)

Broader conditions

Female Urogenital Diseases and Pregnancy Complications (1968)  ·  Female Urogenital Diseases (1967)  ·  Male Urogenital Diseases (1967)  ·  Urogenital Diseases (1967)  ·  Neoplasms, Glandular and Epithelial (1962)  ·  Neoplasms by Histologic Type (1959)  ·  Neoplasms by Site (1959)  ·  Urologic Diseases (1959)  ·  Adenocarcinoma (1953)  ·  Kidney Diseases (1947)  ·  Urogenital Neoplasms (1944)  ·  Urologic Neoplasms (1944)  ·  Carcinoma (1926)  ·  Neoplasms (1810)  ·  Kidney Neoplasms (1488)

Interventions

Sunitinib (145)  ·  Nivolumab (144)  ·  pembrolizumab (139)  ·  Sorafenib (84)  ·  Bevacizumab (78)  ·  Everolimus (74)  ·  cabozantinib (71)  ·  Axitinib (70)  ·  pazopanib (65)  ·  Ipilimumab (64)  ·  aldesleukin (53)  ·  Magnetic Resonance Spectroscopy (47)  ·  Cyclophosphamide (42)  ·  lenvatinib (42)  ·  Interleukin-2 (39)

Sponsors

National Cancer Institute (NCI) (116)  ·  Pfizer (72)  ·  M.D. Anderson Cancer Center (54)  ·  Novartis Pharmaceuticals (35)  ·  Bristol-Myers Squibb (31)  ·  Bayer (29)  ·  Memorial Sloan Kettering Cancer Center (29)  ·  Merck Sharp & Dohme LLC (25)  ·  City of Hope Medical Center (23)  ·  GlaxoSmithKline (21)  ·  Case Comprehensive Cancer Center (19)  ·  Hoffmann-La Roche (17)  ·  Radboud University Medical Center (16)  ·  RenJi Hospital (16)  ·  Jonsson Comprehensive Cancer Center (15)

Countries

United States (1122)  ·  China (214)  ·  France (195)  ·  United Kingdom (161)  ·  Spain (158)  ·  Canada (157)  ·  Italy (149)  ·  Germany (127)  ·  Australia (124)  ·  Netherlands (104)  ·  South Korea (102)  ·  Belgium (78)  ·  Poland (71)  ·  Japan (69)  ·  Russia (66)

Top investigators

Eric Jonasch, MD (12)  ·  Giuseppe Procopio, MD (9)  ·  Sumanta K Pal (9)  ·  Robert J. Motzer, MD (8)  ·  Brian I. Rini, MD (5)

Results publications

PMID 37146227, PMID 27238653, PMID 28410911, PMID 25577718, PMID 33526329, PMID 32499241, PMID 33058158, PMID 39462179, PMID 22980441, PMID 23964934, PMID 26702763, PMID 26706103, PMID 27279544, PMID 31401903, PMID 33947608, PMID 35304832, PMID 35383907, PMID 36848607, PMID 37526095, PMID 41969229, PMID 21917625, PMID 24338498, PMID 24687826, PMID 25532471, PMID 26406150, PMID 26457466, PMID 26685869, PMID 26969090, PMID 27101285, PMID 29377755, PMID 29439857, PMID 29563634, PMID 29788981, PMID 31371341, PMID 31992108, PMID 32171288, PMID 35031545, PMID 35166465, PMID 35420628, PMID 36064785, PMID 37093350, PMID 38396300, PMID 40712111, PMID 40791544, PMID 41484629, PMID 41861260, PMID 10751849, PMID 10984562, PMID 11282341, PMID 11410496

NIH funding

2023 (20), P30CA033572 (20), 2016 (18), 2018 (13), P30CA043703 (13), 2019 (10), 2017 (9), 2008 (8), 2015 (8), P30CA016672 (8), P30CA072720 (8), U10CA032102 (8), U10CA180820 (8), 2014 (7), P30CA014089 (7)